Evidence map›Paper›PMID 28116124›Full record

ArticleFuture science OA2016

The rapid detection of cefotaxime-resistant

Andrew M Robinson, Natalie J Medlicott, James E Ussher

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future science OA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Andrew M RobinsonDepartment of Microbiology & Immunology, University of Otago, Dunedin, New Zealand; Department of Microbiology & Immunology, University of Otago, Dunedin, New Zealand.
Natalie J MedlicottSchool of Pharmacy, University of Otago, Dunedin, New Zealand; School of Pharmacy, University of Otago, Dunedin, New Zealand.
James E UssherDepartment of Microbiology & Immunology, University of Otago, Dunedin, New Zealand; Southern Community Laboratories, Dunedin, New Zealand; Department of Microbiology & Immunology, University of Otago, Dunedin, New Zealand; Southern Community Laboratories, Dunedin, New Zealand.
University of Otago · NZSouthern Community Laboratories (New Zealand) · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimAntibiotic resistance mediated by extended-spectrum β-lactamases (ESBL) and AmpC β-lactamases is widespread and increasingly common, often rendering empiric antibiotic therapy ineffective. In septicemia, delays in initiating effective antibiotic therapy are associated with worse clinical outcomes. With current phenotypic antimicrobial susceptibility testing methods, there is often a delay of 18-24 h before the susceptibility of an isolate is known.

resultsUsing an HPLC assay, breakdown of the third-generation cephalosporin cefotaxime by ESBL- and AmpC- β-lactamase-producing organisms could be detected within 90 min with 86.4% sensitivity and 100% specificity; sensitivity for ESBL detection was 100%.

conclusionThis assay could be readily established in any clinical laboratory with an HPLC to rapidly detect ESBL-producing

Indexed as

AmpC β-lactamasescephalosporin resistanceEnterobacteriaceaeextended-spectrum β-lactamases (ESBL)HPLC

Identifiers

PMID28116124
PMCPMC5242201
OpenAlexW2508601472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.